Enzalutamide: 12 agencies, 2013–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 13.2 years separate the first record, 16 May 2013 at AWMSG (Wales), from the most recent, 2026 at PBAC (Australia).
PBAC (Australia) changed its position: not recommended in 2015, recommended by 2026, after a resubmission.
Every one of the eight highest-volume agencies in this archive has a record for enzalutamide.
Not every gap is a refusal: for enzalutamide, 1 submission was never made and 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 11 of 52 records date from 2023 or later.
The programme is broad: 19 distinct indication wordings are recorded for enzalutamide by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
9 of these 52 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess enzalutamide, on 16 May 2013; DMC (Denmark) did not open a file until 26 May 2021 — an unusually long tail of 8 years between the earliest and latest system to look at it.
The record arrives in waves: 12 separate years each carry two or more decisions, spread across 14 years in total.
12 of the 12 agencies here assessed enzalutamide more than once, PBAC (Australia) most often at 9 entries — repeat review is the norm for this molecule rather than the exception.
enzalutamide has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for enzalutamide reads 25 recommended, 11 not recommended, 5 restricted and 3 deferred to NICE, with 8 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 20 May 2026 | Change to listing conditions (Transparency Committee) | SMR substantial · ASMR III | source |
| CIPM (Spain) | 18 Dec 2024 | Indicaciones terapéuticas autorizadas: Xtandi está indicado en monoterapia o en combinación con la terapia de deprivació… | not financed by the SNS (financed 2025-07) | source |
| SMC (Scotland) | 11 Nov 2024 | As monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensit… | not recommended | source |
| DMC (Denmark) | 28 Aug 2024 | Prostatacancer, Prostatakræft | Ikke anbefalet | source |
| NICE (England) | 8 Aug 2024 | NICE TA994 | terminated appraisal | source |
47 further decisions for enzalutamide, across 12 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 36 further source documents.
Related molecules
- darolutamide — same ATC class L02B — Endocrine therapy
- apalutamide — same ATC class L02B — Endocrine therapy
- abiraterone — same ATC class L02B — Endocrine therapy
- fulvestrant — same ATC class L02B — Endocrine therapy
- relugolix — same ATC class L02B — Endocrine therapy
- elacestrant — same ATC class L02B — Endocrine therapy
Coverage: 52 decisions for enzalutamide from 12 agencies, 2013 to 2026. Data to 7 Sep 2026. ATC class L02B — Endocrine therapy. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.